Phase 3 Myeloma Trial, RecruitingNCT06932562Sponsor: European Myeloma Network B.V.Condition: Myeloma
Printed from Voxsanity (voxsanity.com.au) — NCT06932562 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have been diagnosed with symptomatic multiple myeloma, confirmed using standard international guidelines.
People who have been assessed as not suitable for high-dose chemotherapy followed by a stem cell transplant using their own cells.
People whose myeloma can be measured through standard tests, as defined by the trial.
People who are reasonably functional in daily life, based on a standard health performance scale (scores of 0, 1, or 2 on the ECOG scale).
People whose blood and other lab test results fall within the ranges required by the trial.
Who may not be able to join:
People who score 2 on the International Myeloma Working Group Frailty Index, unless that score is based solely on age.
People who are choosing to delay a stem cell transplant based on personal preference rather than medical reasons.
People with certain related blood or plasma cell conditions, including non-secretory myeloma, active plasma cell leukaemia, AL amyloidosis alongside a myeloma diagnosis, other forms of amyloidosis, Waldenström macroglobulinaemia, or POEMS syndrome.
People who have previously received treatment for early-stage or pre-myeloma conditions (MGUS or smoldering myeloma), or for myeloma itself — with the exception of targeted radiation therapy and/or a short course of steroid treatment as defined by the trial.
People who have received or are currently receiving any experimental treatment or cell therapy that may act against myeloma.
People who have myeloma involvement in the brain or spinal fluid, a history of certain neurological conditions or movement disorders, a history of a serious brain infection called PML, or a history of seizures, mini-strokes, or stroke within the 12 months before starting the trial.
People with serious ongoing illnesses that are not well controlled.
People for whom the trial medications daratumumab or lenalidomide are medically unsuitable, based on local prescribing guidelines.
People who have previously had a bone marrow transplant using cells from another person, or who have had a solid organ transplant at any time.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Roberto Mina, A.O.U. Città della Salute e della Scienza di Torino
Barwon Health, University Hospital Geelong, Geelong,
Austin Hospital, Heidelberg,
Nepean Cancer Centre, Kingswood,
Northern Hospital, Melbourne,
Sunshine Coast Health, Sunshine Coast,
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06932562
Sponsor: European Myeloma Network B.V.
Phase: Phase 3
Status: Recruiting
Condition: Myeloma
Trial contact: +31 10 268 70 65
More information: https://clinicaltrials.gov/study/NCT06932562
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have been diagnosed with symptomatic multiple myeloma, confirmed using standard international guidelines.
People who have been assessed as not suitable for high-dose chemotherapy followed by a stem cell transplant using their own cells.
People whose myeloma can be measured through standard tests, as defined by the trial.
People who are reasonably functional in daily life, based on a standard health performance scale (scores of 0, 1, or 2 on the ECOG scale).
People whose blood and other lab test results fall within the ranges required by the trial.
Who may not be able to join:
People who score 2 on the International Myeloma Working Group Frailty Index, unless that score is based solely on age.
People who are choosing to delay a stem cell transplant based on personal preference rather than medical reasons.
People with certain related blood or plasma cell conditions, including non-secretory myeloma, active plasma cell leukaemia, AL amyloidosis alongside a myeloma diagnosis, other forms of amyloidosis, Waldenström macroglobulinaemia, or POEMS syndrome.
People who have previously received treatment for early-stage or pre-myeloma conditions (MGUS or smoldering myeloma), or for myeloma itself — with the exception of targeted radiation therapy and/or a short course of steroid treatment as defined by the trial.
People who have received or are currently receiving any experimental treatment or cell therapy that may act against myeloma.
People who have myeloma involvement in the brain or spinal fluid, a history of certain neurological conditions or movement disorders, a history of a serious brain infection called PML, or a history of seizures, mini-strokes, or stroke within the 12 months before starting the trial.
People with serious ongoing illnesses that are not well controlled.
People for whom the trial medications daratumumab or lenalidomide are medically unsuitable, based on local prescribing guidelines.
People who have previously had a bone marrow transplant using cells from another person, or who have had a solid organ transplant at any time.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
European Myeloma Network B.V.
Registry
ClinicalTrials.gov
Start date
23 December 2025
Est. completion
1 December 2036
Where this trial is recruiting
🇦🇺 Australia
🇦🇹 Austria
🇭🇷 Croatia
🇨🇿 Czechia
🇩🇰 Denmark
🇪🇪 Estonia
🇫🇮 Finland
🇩🇪 Germany
🇬🇷 Greece
🇮🇪 Ireland
🇮🇹 Italy
🇳🇱 Netherlands
🇳🇴 Norway
🇵🇹 Portugal
🇪🇸 Spain
🇸🇪 Sweden
🇨🇭 Switzerland
Turkey (Türkiye)
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Minimal Residual Disease (MRD); MRD negative CR status by BICR; Progression Free Survival (PFS) per IMWG criteria; PFS as determined by BICR
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.